Pricing issues have taken precedence as CVS Health’s (NYSE:CVS) pharmacy benefit manager, CVS Caremark, continues to hold off ...

(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not to add the former’s new HIV prevention drug, Yeztugo (lenacapavir), to its ...

Gilead stock toppled Thursday after CVS HealthCVS said it won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now. The decision is based on clinical, financial and ...

Merck's two-drug HIV regimen doravirine/islatravir maintained viral suppression and matched Gilead's Biktarvy in Phase 3 ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

Health experts are sounding the alarm over a disturbing trend where drug users swap blood to score a secondhand high. Called “bluetoothing,” the gruesome movement is fueling a wave of new HIV ...